Lexington, MA - May 22, 2013 - Agenus Inc. (NASDAQ: AGEN) today announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 (Heat Shock Protein Peptide Complex-96 or HSPPC-96) vaccine in combination with ...

Lexington, MA - May 1, 2013 - Agenus Inc. (NASDAQ: AGEN) today announced that preliminary data from a Phase 2 clinical trial showed that newly diagnosed glioblastoma multiforme (GBM) patients treated with Prophage G-100 (Heat Shock Protein-Peptide ...

Lexington, MA - April 24, 2013 - Agenus Inc. (NASDAQ: AGEN), a biotechnology company working to develop novel immunology based treatments for cancers and infectious diseases, today announced its financial results and business highlights for the first ...

Agenus Q1 13 Earnings Conference Call At 11:00 AM ET. By RTT News, April 24, 2013, 10:00:00 AM EDT. Vote up. loading. (RTTNews.com) - Agenus Inc.( AGEN ) will host a conference call at 11:00 AM ETApril 24, 2013, to discuss its Q1 13 earnings results.

Star Scientific, Inc. (NASDAQ:STSI) fell -3.23% to move at $1.20 after disclosing that its second cosmetic product, Anatabloc Revitalizing Facial Serum, is now being sold on the website of vitamins and supplements retailer GNC.

... 16.6 CYTK CYTOKINETICS INC 1,314,674 1,127,760 16.6 CCRN CROSS COUNTRY HE 465,036 398,988 16.6 RBCN RUBICON TECHNOLO 4,847,714 4,161,674 16.5 UPIP UNWIRED PLANET I 2,076,745 1,783,254 16.5 AGEN AGENUS INC 1,343,896 ...

Agenus Inc., formerly Antigenics Inc., develops and commercializes immunotherapies for cancer and infectious diseases. To view Zacks' full report, visit www.

The HSPCC-96 vaccine (Prophage G-100, Agenus Inc) is an autologous treatment derived from dendritic cells extracted from the patient's tumor.

... protein-peptide complex-96 (HSPPC-96; Prophage G-100, Agenus Inc.) vaccine. They assigned 46 patients with newly diagnosed glioblastoma multiforme to receive the HSPPC-96 vaccination in addition to standard care of radiation and temozolomide.

(RTTNews.com) - Agenus Inc. ( AGEN ) said that its brain cancer vaccine candidate - Prophage G-100, plus the standard of care demonstrated a 146% increase in progression free survival and a 60% increase in overall survival compared to the standard of ...